Company:  INFINITY PHARMACEUTICALS, ... (INFI)
Form Type:  8-K
Filing Date:  12/26/2012 
CIK:  0001113148 
Address:  780 MEMORIAL DRIVE 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  (617) 453-1000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$9.94  
Change: 
-0.03 (-0.30%)  
Trade Time: 
Apr 24  
Market Cap: 
$479.91M
Description of Business
We are an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. We combine proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. We have worldwide development and commercialization rights to all of our development candidates and early discovery programs, subject to certain financial obligations to our current licensor and former development partners. IPI-145, our lead product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which we are investigating in both hematologic malignancies and inflammatory diseases. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry into a Material Definitive Agreement
    SECTION 8 OTHER EVENTS
      Item 8.01. Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 99.1
BROKERAGE PARTNERS